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 Multicentre, cohort study of 3416 women (aged >70 years) with breast cancer 
 In older women with high-risk, early breast cancer, chemotherapy reduces quality of life. 
 Relevant affected domains include cognition, fatigue, physical, role and social functioning. 






Older patients with early breast cancer (EBC) derive modest survival benefit from chemotherapy but 
have increased toxicity risk. Data on the impact of chemotherapy for EBC on quality-of-life in older 
patients are limited, but this is a key determinant of treatment acceptance. We aimed to investigate 
its effect on quality-of-life in older patients enrolled in the Bridging the Age Gap study. 
Materials and methods 
A prospective, multicentre, observational study of EBC patients 70 years old was conducted in 2013-
2018 at 56 UK hospitals. Demographics, patient, tumour characteristics, treatments and adverse 
events were recorded. Quality-of-life was assessed using the European Organisation for Research and 
Treatment of Cancer Quality-of-Life Questionnaires [EORTC-QLQ] C30, BR23 and ELD 15 plus the 
Euroqol-5D [EQ5D] over 24 months and analysed at each time point using baseline adjusted linear 
regression analysis and propensity score-matching. 
Results 
3416 patients were enrolled in the study; 1520 patients undergoing surgery and who had high-risk 
EBC were included in this analysis. 376/1520 (24.7%) received chemotherapy. At 6 months, 
chemotherapy had a significant negative impact in several EORTC-QLQ-C30 domains, including global 
health score, physical, role, social functioning, cognition, fatigue, nausea/vomiting, dyspnoea, 
appetite loss, diarrhoea and constipation. Similar trends were documented on other scales (EORTC-
QLQ-BR23, EORTC-QLQ-ELD15 and EQ-5D-5L). Its impact was no longer significant at 18-24 months in 
unmatched and matched cohorts.  
Conclusions 
The negative impact of chemotherapy on quality-of-life is clinically and statistically significant at 6 
months but resolves by 18 months, which is crucial to inform decision-making for older patients 
contemplating chemotherapy.  
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Almost half of all breast cancer cases are diagnosed in patients aged 65 years.[1] Nonetheless, older 
adults are under-represented in clinical trials.[2] Moreover, standard trial endpoints may not be 
appropriate for older individuals and quality of life (QoL), functional status and cognition may be as 
important as chance of cure.[3] These knowledge gaps contribute to considerable variation in 
treatment in this age group.[4]  
Curative chemotherapy is associated with a survival benefit only in patients with node-positive and 
oestrogen receptor (ER)-negative disease.[5, 6] Older adults have higher risk of treatment toxicities 
due to comorbidities and reduced organ function, while benefits are mitigated by competing risks.[7] 
The impact of chemotherapy on QoL may influence clinicians’ a d patie ts’ perspectives.[8]  
Therefore, the effect of anticancer treatments on QoL is essential to inform treatment decisions in 
this cohort. The CALGB 49907 study documented better QoL for patients aged 65 receiving 
capecitabine versus standard regimens but no QoL differences persisted at 1 year.[9] Patients 
receiving chemotherapy within clinical trials had better QoL improvements compared with those 
treated off study.[10] Nonetheless, prospective data on QoL for older patients with early breast cancer 
(EBC) receiving standard chemotherapy are lacking. 
Comorbidities, literacy, symptoms and compliance may influence patient-reported outcomes,[11] but 
the European Organisation for Research and Treatment of Cancer (EORTC) questionnaires have been 
validated to evaluate QoL generically in cancer patients,[12] and specifically in older individuals[13] 
and in those diagnosed with breast cancer.[14] 
We aimed to investigate the impact of chemotherapy on QoL in real-world EBC patients aged 70 
recruited to the Bridging the Age Gap study.[15]  Matching survival outcomes for the cohort are 





Ethics approval (IRAS: 12 LO 1808) and research governance approval were obtained. All patients (or 
their proxies, if cognitively impaired) gave written informed consent.  
 
Study design 
Bridging the Age Gap is a prospective multicentre, observational cohort study. Patients were recruited 
from 56 UK centres in England and Wales (Table S . Eligi le patie ts ere o e  7  ears at 
diagnosis of operable invasive breast cancer (TNM stages: T1-3, plus some operable T4b, N0-1, M0). 
Those unsuitable for surgery or with previous EBC within five years were not eligible.  
 
Baseline data collection 
Patients were recruited at the time of diagnosis and could participate at three levels: full, partial (no 
requirement to complete QoL assessments) or proxy (simple third-party data collection for those with 
cognitive impairment). 
Primary tumour characteristics were collected at baseline. Staging was performed if indicated. 
Surgery, radiotherapy and systemic treatment data were also collected. 
Baseline geriatric assessments included comorbidities (Charlson comorbidity index [CCI])[16], 
nutrition (Abridged Patient Generated Subjective Global Assessment [aPG-SGA])[17-19], functional 
status (Eastern Cooperative Oncology Group Performance status (ECOG PS), Activities of Daily Living 
[ADL],[20] Instrumental Activities of Daily Living [IADL])[21], cognition (Mini Mental State Examination 
[MMSE])[22], and medications. Patients were classified as high-risk ased o   of the follo i g 
criteria:  1) HER2-positive status; 2) ER- egati e status;  grade ;   alig a t l ph ode;  
Re urre e S ore RS   Ta le S . 
QoL was evaluated using four questionnaires. The EORTC QLQ-C30 includes five functions (physical, 
role, emotional, cognitive and social), nine symptoms (fatigue, nausea and vomiting, pain, dyspnoea, 
insomnia, appetite loss, constipation, diarrhoea and financial difficulties) and global health status.[12] 
The EORTC-QLQ-BR23 comprises 23 questions evaluating body image, sexual functioning and 
enjoyment, future perspective, systemic therapy side effects, breast symptoms, arm symptoms and 
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frustration with hair loss.[14] The EORTC-QLQ-ELD15 contains five scales (functional independence, 
relationships with family and friends, worries about the future, autonomy and burden of illness).[13] 
The EQ-5D-5L was used in this analysis to assess overall QoL[23] and individual questions were scored 
separately from 1-5.   
Patients were followed up at 6 weeks, 6, 12, 18 and 24 months and QoL and side-effects, based on the 
Common Terminology Criteria for Adverse Events (CTCAE v4.0), were assessed at each visit. 
 
Statistical analyses 
Analyses were performed in IBM SPSS statistics version 24 and R version 3.6.3.[24, 25] A p <0.05 was 
considered statistically significant. 
The questionnaires were scored according to the EORTC Scoring Manual (3rd Edition).[13] Missing data 
were managed accordingly. The analysis included high-risk EBC patients where QoL questionnaires 
were available. The mean difference (95% CI) of the domain scores at each time point, adjusted for 
baseline scores, was calculated with linear regression models for high-risk participants. Effect sizes 
after analyses of the EORTC-QLQ-C30 will be categorised as either trivial, small, medium or large 
according to pre-specified thresholds for each domain.[26] 
The chemotherapy effect on the global health score over time for high-risk patients was estimated 
using a mixed-effect linear model. The model allowed for time, treatment, treatment-time interaction, 
and baseline global health status. Differences between the chemotherapy and non-chemotherapy 
groups were derived at each timepoint using linear contrasts. The model was fitted to high-risk 
patients and to the propensity score-matched patients only. For the unmatched analysis the model 
also adjusted for age and baseline functionality scores.  
We also performed propensity score-matching to compare the EORTC-QLQ-C30 global health score 
and the EQ-5D-5L usual activities score in a matched cohort receiving chemotherapy versus patients 
not receiving it. Logistic regression was used to calculate propensity scores for treatment allocation in 
high-risk patients. These were used to match chemotherapy patients to those who did not receive 
chemotherapy based on ADL, IADL, MMSE, ECOG, aPG-SGA, CCI, number of medications, and age. The 
ratio and calliper widths of the propensity scores were chosen based on examination of propensity 
score overlaps for several combinations of ratios and callipers. A 1:3 ratio for chemotherapy to no 
chemotherapy and a calliper of 0.25 times the propensity scores standard deviation was used to 
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optimally match quality and numbers. Participants were matched on Nottingham Prognostic Index 




Between January 2013 and June 2018, 3456 women were recruited from 56 hospitals in England and 
Wales and 3416 included in the analysis. 2811/3416 (82.3%) underwent surgery within 6 months of 
diagnosis, 1520/2811 (54.1%) had high-risk EBC and 376/1520 (24.7%) received chemotherapy. 
(Figure 1)[27]. The time frames for treatments received in each cohort are shown in Figure S1 wherein 
the slight offset in timing of endocrine therapy and RT between the chemotherapy and no 
chemotherapy groups can be seen and should be considered when interpreting the findings. 
Patients had a median age of 76.9 years, CCI of 1 (range 0-9) and took a median of 4 medications (0-
18); 1063 (69.9%) were independent in their ADLs and 1091 (71.8%) in their IADLs, 1346 (88.6%) had 
normal MMSE, 1168 (76.8%) had a low aPG-SGA score and 1379 (90.7%) had ECOG PS 0-1 (Table 1). 
Chemotherapy data were available for 360 patients: 124 (34.4%) received anthracycline and taxanes, 
119 (33.1%) a taxane alone, and 116 (32.2%) an anthracycline alone; one patient received 
cyclophosphamide, methotrexate, fluorouracil (CMF). 332 patients (21.8%) had HER2-positive 
disease: 150 (45.2%) received chemotherapy plus trastuzumab, 13 (3.9%) received trastuzumab alone, 
and 9 (2.7%) chemotherapy alone. EBC was ER-positive in 1134 patients (75.3%), with 1079 (95.1%) 
receiving endocrine therapy (Figure S1).   
Of these high-risk patients, 1120 (73.7%) enrolled with full participation in the protocol (necessary for 
completion of QoL questionnaires) and 304/1120 (27.1%) had chemotherapy. Figures S2-S4 and Tables 
S3-5 show completion rates of QoL questionnaires. 
 
Impact on QoL domains (EORTC QLQ-C30)  
1049/1120 patients (93.7%) completed the global health status questions included in the EORTC QLQ-
C30 questionnaire at baseline (Table S6a; Figure 2). Following adjustment for baseline scores, at 6 
weeks the differences in the mean scores on some EORTC QLQ-C30 domains were statistically 
significant between patients undergoing chemotherapy compared to those not receiving it, including 
global health (adjusted mean difference -2.81, 95% CI -5.17 to -0.44, p=0.020), social functioning (-
3.57, CI -6.71 to -0.43, p=0.026) and constipation (3.43, CI 0.23 to 6.62, p=0.035). The impact of 
chemotherapy remained significant on most domains at 6 months, including global health which was 
both statistically and clinically significant but small (-9.20, CI -11.95 to -6.44, p <0.001), physical 
functioning (medium difference: -8.05, CI -10.21 to -5.89, p<0.001), role functioning (small difference: 
-17.59, CI -21.24 to -13.95, p<0.001), cognitive functioning (small difference: -5.55, CI -7.97 to -3.13, 
p<0.001), social functioning (large difference: -18.72, CI -22.17 to -15.27, p<0.001), and financial 
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problems (small difference: 3.28, CI 1.16 to 5.39, p=0.002). At 12 months statistically significant 
differences persisted in physical functioning (trivial difference: -2.76, CI -4.95 to -0.57, p=0.014), role 
functioning (trivial difference: -4.41, CI -8.17 to -0.64, p=0.022), social functioning (trivial difference: -
3.78, CI -7.00 to -0.56, p=0.022), diarrhoea (small difference: 4.15, CI 1.62 to 6.68, p=0.001) and 
financial problems (trivial difference: 2.50, CI 0.27 to 4.73, p=0.028). Chemotherapy was no longer 
impactful in any of these domains at 18 and 24 months.  
The analyses were repeated on a propensity score-matched subgroup of 410 patients (150 
chemotherapy, 260 no chemotherapy) with similar findings (Figure S5-7; Table S6b). 
 
Impact on breast cancer-specific QoL domains (EORTC QLQ-BR23) 
1054/1120 patients (94.1%) completed some or all of the EORTC QLQ-BR23 questionnaire at baseline 
(Figure 3; Table S7). After adjustment for baseline measurements patients given chemotherapy 
experienced a significant decline of some EORTC QLQ-BR23 mean scores at 6 weeks compared with 
those not receiving it in future perspective (adjusted mean difference -7.20, 95% CI -10.72 to -3.68, 
p<0.001) and systemic therapy side-effects (3.04, CI 1.47 to 4.61, p<0.001). At 6 months, mean scores 
were significantly different in future perspectives (-7.54, CI -11.28 to -3.80, p<0.001) and systemic 
therapy side-effects (16.97, CI 15.00 to 18.94, p<0.001). At 12 months, the mean scores between the 
two groups differed in future perspectives (-4.96, CI -8.89 to -1.03, p=0.013), systemic therapy side-
effects (3.32, CI 1.41 to 5.22, p=0.001) and the effect of chemotherapy became significant in arm 
symptoms (4.94, CI 2.18 to 7.69, p<0.001). At 18 months, the differences remained significant in future 
perspective (-4.97, CI -9.37 to -0.57, p=0.027) and arm symptoms (3.27, CI 0.01 to 6.54, p=0.049), and 
at 24 months only in arm symptoms (4.02, CI 0.13 to 7.90, p=0.043).  
 
Impact on older adults-specific QoL domains (EORTC QLQ-ELD15) 
Some or all of the EORTC QLQ-ELD15 questionnaire was completed at baseline by 1048/1120 (Table 
S8; Figure 4). At 6 weeks scores were significantly different between patients given chemotherapy and 
those not treated in worries about others (adjusted mean difference 5.31, 95% CI 1.55 to 9.07, 
p=0.006), worries (4.09, CI 0.92 to 7.27, p=0.011) and burden of illness (4.68, CI 1.25 to 8.11, p=0.007). 
These differences persisted at 6 months (worries about others [6.19, CI 2.44 to 9.95, p=0.001]; worries 
[4.18, CI 0.89 to 7.46, p=0.013]; burden of illness [21.60, CI 17.82 to 25.39, p<0.001]); the impact on 
mobility also became significant (9.82, CI 6.87 to 12.78, p<0.001). At 12 months, changes remained 
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significant regarding worries about others (4.47, CI 0.42 to 8.52, p=0.031) and burden of illness (15.21, 
CI 11.30 to 19.12, p<0.001), which was the only domain significantly influenced also at 18 months 
(12.99, CI 8.81 to 17.17, p<0.001) and 24 months (8.80, CI 3.93 to 13.66, p<0.001). 
Maintaining purpose did not differ throughout the follow-up period, whereas chemotherapy had a 
positive impact on family support mean scores at 6 weeks (6.21, CI 2.26 to 10.17, p=0.002), at 6 
months (4.91, CI 0.26 to 9.56, p=0.038) and at 12 months (5.43, CI 0.39 to 10.46, p=0.035). 
 
Impact on EQ-5D-5L score and questions 
Among the high-risk patients, an EQ-5D-5L score was calculated in 1315 patients (86.5%) at baseline. 
Health utilities were similar with estimated mean differences less than 0.02 units (p>0.1), whereas the 
visual analogue scale (VAS) measures were significantly worse at 6 months in patients receiving 
chemotherapy versus not (adjusted mean difference -6.57, 95% CI -8.74 to -4.40, p<0.001). Changes 
were subsequently no longer significant (Table S9; Figure 5).  
A similar pattern on EQ-5D-5L usual activities score was seen in 520 (118 chemotherapy, 332 no 





This study demonstrates that chemotherapy has a both a clinically and statistically significantly 
negative impact at 6-12 months on several QoL domains (physical, role, cognitive and social 
functioning, financial problems), symptoms (fatigue, nausea, dyspnoea, appetite loss, constipation, 
diarrhoea), and perceived global health. These changes are clinically meaningful and involve key 
domains for this population[28] for whom even low-grade toxicities may be challenging.[29] 
Reassuringly, this effect resolves for most items over 18-24 months, which is consistent with previous 
QoL data reported in younger cohorts: for example, in 280 EBC patients many domains improved 
within 12 months after diagnosis, with the exception of cognitive function and financial problems[30] 
and similar improvements in role functioning were seen in a study of 817 EBC patients.[31] A registry-
based analysis documented better physical functioning, role-physical, role-emotional and fatigue 
scales at 15 years in EBC patients including 46.9% aged 65.[32] Similarly, 588 EBC patients enrolled 
in the Moving Beyond Cancer study had improved physical and psychosocial functioning after radical 
treatment regardless of chemotherapy use.[31] Neuropsychological analyses also confirmed 
improving cognitive function during the first four years after radical therapy for EBC,[33, 34] although 
data on financial impact are limited.[30] The CANTO study confirmed the transient nature of the 
impact of chemotherapy on QoL in a large population.[35] Nonetheless, these analyses have either 
focused on younger patients, where the risk/benefit is different, or addressed the impact of breast 
cancer treatments (and not specifically of chemotherapy) on QoL in this age group. Our findings are 
consistent with a previous study in 109 patients aged 70 or older, of whom 57  received adjuvant 
docetaxel/cyclophosphamide chemotherapy.[36]   
To our knowledge, this is the largest study to evaluate the impact of contemporary chemotherapy 
regimens in older adults with EBC in real-world patients. QoL is a meaningful endpoint for older 
patients, who typically derive less survival benefit and increased toxicities on systemic anticancer 
treatments.[37, 38] These benefits need to be carefully balanced with the detrimental impact on QoL 
and treatment side-effects.[39]  
Our analysis included baseline geriatric assessments characterizing patients in relevant health 
domains for this age group, such as functional status, comorbidity, cognition, nutrition and concurrent 
medications which may impact QoL. A comprehensive geriatric assessment can help achieve the 
required balance between treatment benefits and side-effects and is recommended by guidelines 
from the American Society of Clinical Oncology, the National Comprehensive Cancer Network, and the 
International Society for Geriatric Oncology.[28, 40] In a randomized study, integrated oncogeriatric 
care has recently been shown to improve QoL in older patients with cancer being considered for 
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systemic anticancer therapy.[41] Of particular interest was our finding that in patients 80 the 
negative impact on QoL does not resolve, which suggests a lack of resilience in this cohort.   
The study has several limitations.  Selection bias may have influenced our findings despite its inclusive 
entry criteria and the different levels of participation. The recruited population was slightly skewed 
towards younger individuals compared with the general UK EBC patient population.[42]  Moreover, 
we did not include socio-economic factors that might influence frailty nor the effect of endocrine 
therapy or radiotherapy on QoL, owing to multiple confounders to such an analysis. We did not 
capture the impact of chemotherapy on QoL outcomes beyond 24 months and missing data on 
longitudinal QoL assessments may have influenced findings. Other factors not measured by our 
analysis may also impact on chemotherapy decisions; therefore, the propensity score matching does 
not adjust for all differences between the groups. Furthermore, some effects of chemotherapy on QoL 
documented in our analysis might be statistically significant but not clinically relevant, although for 
the majority of domains clinically meaningful changes are seen at the six-month timepoint, which 
represents the time when most women would have been on chemotherapy. Finally, it was not possible 
to categorise chemotherapy effects on QoL measured on BR23, ELD15 and EQ-5D-5L domains as 
thresholds have not been established for these specific tools and the latter is a utility scale. 
In conclusion, our analysis shows that chemotherapy has an impact on several QoL domains in older 
EBC patients compared to a matched cohort who did not receive cytotoxics. Nonetheless, these effects 
are temporary and largely resolve within two years. This is essential information for older women to 






 Figure 1 – STROBE flow diagram for the chemotherapy versus no chemotherapy analyses. 
 Figure 2 – Mean (95% CI) scores over time points for the chemotherapy versus no 
chemotherapy population measured on the EORTC-QLQ-C30 scale. 
 Figure 3 – Mean (95% CI) scores over time points for the chemotherapy versus no 
chemotherapy population measured on the EORTC-QLQ-B23 scale. 
 Figure 4 – Mean (95% CI) scores over time points for the chemotherapy versus no 
chemotherapy population measured on the EORTC-QLQ-ELD15 scale. 
 Figure 5 – Mean (95% CI) scores over time points for the chemotherapy versus no 
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